Kornimate/medical-research-clean huggingface dataset:
vitamin d supplementation and and glycemic indexes

Conditions: Deficiency, Vitamin D; Insulin Resistance

Summary: age affect insulin sensitivity and the metabolism, and vitamin d status was shown to have a correlation with markers of insulin resistance. that's why, we aimed in our trial to study the effect of vitamin d supplementation on glycemic markers and index of insulin resistance.

a low serum 25-hydroxyvitamin d \[(25(oh) d)\] concentration was shown to correlate with higher fasting blood glucose (fbg) and insulin levels. since age affect insulin sensitivity and the metabolism, we aimed in this randomized controlled trial to investigate the effect of vitamin d supplementation on glucose homeostasis and index of insulin resistance in elderly subjects living in beirut, lebanon. participants (n= 115) deficient in vitamin d were randomly divided into two groups, a group receiving 30,000 iu cholecalciferol/week for a period of 6 months, and a placebo group. the index of insulin resistance homa (homeostasis model assessment) was the primary outcome. glucose homeostasis and metabolic markers were also measured at start of treatment and at 6 months.

Eligibility criteria:
inclusion criteria: -deficiency in vitamin d and having no medical history of type 2 diabetes mellitus exclusion criteria: patients with a history of type-2-diabetes, congestive heart failure, liver failure, renal failure, cancer, or taking oral hypoglycemic drugs or statin therapy, or patients having metabolic bone disease.

Keywords: vitamin d homa-ir glucose hba1c insulin resistance
adjunctive treatment for chronic rhinosinusitis with nasal polyposis

Conditions: Chronic Rhinosinusitis; Nasal Polyps

Summary: this is a research study to find out if an off-label use of carboxymethylcellulose foam (cmc), an absorbable nasal packing, combined with triamcinolone acetonide, a steroid, is more comfortable postoperatively for participants and is as effective in decreasing scarring, swelling and crusting after surgery than an fda approved steroid eluting implant. anticipated sample size will be 30. study is an intrapatient control design. subjects will be randomly assigned to receive cmc foam with triamcinolone in one nare and the steroid-eluting implant in the other. participants will fill out preoperative and follow-up visit surveys at 7, 14, 30 and 90 days. subjects at each visit will also have pictures taken of the nasal cavities to be scored for later analysis. paired t-tests will be performed for analysis. our primary objective is to demonstrate that triamcinolone-impregnated carboxymethylcellulose foam is noninferior to steroid-eluting implants in improving postoperative ethmoid inflammation, middle turbinate position, preventing intranasal synechiae and reducing polypoid change with objective measurement scales our secondary objects include assessing the quality-of-life and nasal obstruction symptoms before and after functional endoscopic sinus surgery with validated snot-22 and nose questionnaires and to assess the cost-effectiveness of triamcinolone-impregnated carboxymethylcellulose foam versus steroid-eluting implant in management of crswnp in the early postoperative period. the endpoints are the pose scores, the snot-22 and nose scores at days 7, 14, 30 and 90.


Eligibility criteria:
inclusion criteria: * provision of signed and dated informed consent form * stated willingness to comply with all study procedures and availability for the duration of the study * diagnosis of nasal polyposis and desiring surgery exclusion criteria: * a known history of intolerance to corticosteroids * an oral steroid-dependent condition * a history of immune deficiency * pre-existing narrow angle glaucoma or cataracts * subjects that did not complete the pre-op medical regimen described below * pregnant and/or breastfeeding
prostate cancer education in african american men

Conditions: Prostate Cancer Screening Decision

Summary: this study evaluates the efficacy of a tailored telephone intervention to promote informed decision making about prostate cancer testing among predominantly immigrant black men.

african american and african-caribbean men have the greatest prostate cancer incidence and mortality rate. professional organizations provide conflicting recommendations regarding prostate cancer testing but generally agree that men learn about the risks and benefits of testing and share in decisions about testing based on their personal preferences. this study was designed to assess the effects of a decision support intervention on men's knowledge about prostate cancer testing, participation in medical decisions about testing, decision conflict related to testing, and the congruence between prostate cancer testing intentions and behaviors. a randomized controlled trial was conducted. participants were randomized into one of two conditions: (a) tailored telephone education about prostate cancer testing (intervention group) or (b) tailored telephone education about national guidelines for fruit and vegetable consumption (attention control group).

Eligibility criteria:
inclusion criteria: * 45 to 70 year old * african descent * accessible by telephone * have primary care physician exclusion criteria: * prostate cancer test in 12 months prior to enrollment * history of prostate cancer

Keywords: prostate-specific antigen (146-154) prostate-specific antigen (154-163)
64cu-llp2a for imaging hematologic malignancies

Conditions: Multiple Myeloma; Low-Grade Lymphoma; Follicular Lymphoma; Marginal Zone Lymphoma; Lymphoplasmacytic Lymphoma; Small Lymphocytic Lymphoma; Chronic Lymphocytic Leukemia

Summary: this phase of the protocol (protocol part b), seeks to evaluate the new formulation in healthy normal volunteers to confirm the new formulation provides comparable human dosimetry to which was seen and published in protocol part a. additionally, the new formulation will be studied utilizing an expanded patient population to include patients with confirmed diagnosis of multiple myeloma (mm), low-grade lymphoma, or mm and lymphoma patients who are status post bone marrow transplant (bmt) with negative imaging and suspected recurrence.


Eligibility criteria:
inclusion criteria healthy volunteer: * adult 18 years of age or older * able to give informed consent. * able to comprehend and willing to follow instructions for study procedures as called for by the protocol * capable of lying still and supine within the pet/ct scanner for up to 75 minutes. * no illicit drug use or other inhaled drug use (including pharmacologic agents and illicit drugs) within the past year per self-reporting mechanisms. * no history of claustrophobia or other condition that has previously or would interfere with completion of protocol specified imaging sessions. * not currently pregnant or nursing: subject must be surgically sterile (has had a documented bilateral oophorectomy and/or documented hysterectomy), post-menopausal (cessation of menses for more than 1 year), non-lactating, or of childbearing potential for whom a urine pregnancy test (with the test performed within the 24 hour period immediately prior to administration of 64cu-llp2a) is negative. inclusion criteria hematological malignancy: * clinical or pathologically defined mm or lymphoma including both newly diagnosed, relapsed or refractory disease: * multiple myeloma defined in accordance with the international myeloma working group criteria * low-grade lymphoma, including the following subtypes: follicular lymphoma, marginal zone lymphoma, lymphoplasmacytic lymphoma, small lymphocytic lymphoma/chronic lymphocytic leukemia * adult 18 years of age or older and able to provide informed consent * capable of lying still and supine within the pet/ct scanner for up to 75 minutes. * no history of claustrophobia or other condition that has previously or would interfere with completion of protocol specified imaging sessions * not currently pregnant or nursing: subject must be surgically sterile (has had a documented bilateral oophorectomy and/or documented hysterectomy), post-menopausal (cessation of menses for more than 1 year), non-lactating, or of childbearing potential for whom a urine pregnancy test (with the test performed within the 24 hour period immediately prior to administration of 64cu-llp2a) is negative * patients participating in imaging or therapeutic trials with investigational agents are eligible to participate

Keywords: pet imaging
effectiveness of a modern educational intervention in breast cancer patients

Conditions: Breast Neoplasm; Pain

Summary: in addition to fatigue, pain is the most frequent and persistent symptom following breast cancer and breast cancer treatment. despite the effectiveness of different physical therapy modalities, such as manual techniques, passive mobilizations and exercises, many patients still experience pain and subsequent difficulties in daily functioning at short and long term. past decades, the awareness on the important role of educational interventions in the management of pain in general has increased. educational interventions aim at explaining and improving the knowledge, control and attitude of the patient regarding his/her pain complaint. however, these educational interventions are often restricted to more biomedical pain management instructions and general advice on physical activity and analgesics (= traditional biomedical education). only recently, increased knowledge on pain mechanisms led to a more modern educational approach. this modern approach is suited to explain more complex issues associated with pain and takes into account many more factors related to pain. to our knowledge, only one controlled trial investigated the effectiveness of a modern educational intervention in the early stage of breast cancer treatment. the results were very promising for shoulder function. however, only short-term effects were examined, no randomization was performed and no pain-related and socio-economic outcomes were evaluated. therefore, the aim of the proposed project is to investigate the effectiveness of a similar modern educational program, in addition to standard physical therapy care, in the early treatment phase of breast cancer in comparison with traditional biomedical education. a randomized controlled trial will be performed with a long-term follow up period. the primary outcome parameter is pain-related disability. secondary outcomes are different dimensions of pain, physical and mental functioning, return to work and health-care related costs.


Eligibility criteria:
inclusion criteria: * patients with primary breast cancer * unilateral surgery including, either: axillary lymph node dissection and mastectomy/breast -conserving/reconstructive surgery or sentinel node biopsy and mastectomy/reconstructive surgery exclusion criteria: * active metastasis * cannot participate during the entire study period
eye movement and cognitive dysfunction

Conditions: Eye Movement Disorder; Cognitive Dysfunction

Summary: there is association between eye movement disorder and cognitive dysfunction. therefore, utilizing eye movement and screening for cognitive dysfunction is feasible. in the present study, we will develop an artificial intelligence platform to screening for cognitive dysfunction by inspecting the function of eye movement. futher more, based on the screening results, the platform will offer referral suggestions.


Eligibility criteria:
inclusion criteria: * ①subjects who are diagnosed as mild cognitive decline, alzheimer's disease, vascular dementia, lewy body dementia, frontotemporal dementia, other dementia and normal by neurologist. * ②subjects who can cooperate with the inspection. * ③subjects who agree to participate in the study and sign the consent form exclusion criteria: * ①subjects who cannot do the inspection. * ②subjects who suffer from diseases that compromise the inspection.
hydralazine versus labetalol for the management of hypertensive disorders of pregnancy

Conditions: Hypertension, Pregnancy Induced

Summary: hypertensive crisis (defined as a systolic pressure \> 160mmhg or a diastolic pressure \> 110mmhg) in patients with a hypertensive disorder of pregnancy is a serious complication with severe and even deadly consequences. the management in this population had been studied, but no consensus has been reached with regards to which treatment is better. our study will compare two drugs: hydralazine and labetalol for the management of hypertensive crisis.


Eligibility criteria:
inclusion criteria: * gestational age \> 24 weeks. * hypertensive crisis (systolic pressure \> 160 mmhg / diastolic pressure \< 110mmhg). exclusion criteria: * known allergy to hydralazine. * known allergy to labetalol. * severe bradycardia

Keywords: hypertension, pregnancy induced hydralazine labetalol
management of atrial fibrillation with flecainide : the afflec study

Conditions: Atrial Fibrillation

Summary: this is a multicentre non interventional observational study with the objective to follow up patients with atrial fibrillation who based on current indications are treated with per os flecainide , for cardiac pulse maintenance.

the study objectives are * record safety and efficiency of flecainide as antiarrythmic treatment in atrial fibrillation * study of flecainide in st interval

Eligibility criteria:
inclusion criteria: * patients with history of atrial fibrillation * patients able to give informed consent exclusion criteria: * patients with coronary disease or other cardiopathy with left heart champer affected
effect of intake in bioactive molecules from natural or pasteurised milk on gut maturation in very premature newborns

Conditions: Premature Birth

Summary: it seems important to correlate real consumption in bioactives molecules of natural milk versus pasteurized with gut maturation in very preterm infants during small enteral feeding protocol. this objective will be reached through a clinical trial.

one hundred infants born between 28 and 30 weeks of gestational age will be enrolled in our clinical trial in two neonatal units of marseille; they will receive small enteral feeding protocol with natural or pasteurized milk (according to the neonatology department). infants monitoring will be conducted from birth until 32 weeks of gestational age through extra-uterine growth, dietary type evolution and determination of gut maturation markers levels in blood (triglycerides and cholesterol, pufa, glp-2, i and l-fabp, gastrin, citrullin) and faeces (calprotectine). we will also look for new biological markers of intestinal growth, via metabolomic approach. consumption of bioactives molecules (pufa, sphingomyelin, scd14, insulin, leptin, lactoferrin, sphingomyelinase acid and bssl activity) will be quantified in milk 24h-representative samples received by each newborn. the benefits on digestive tract physiology evolution due to the molecules consumption will be observed from the 32nd week until the 36th week or the end of hospitalization.

Eligibility criteria:
inclusion criteria: * children whose term is understood(included) between 28 (27sa+6j past(over)) and 30 limited companies (30 sa+6j). * children fed by digestive stimulation. * children in 1st day of food(supply) * term of certain child. * children not presenting a genic syndrome, an evolutionary neurological disease, a pathology malformative. * children among whom both holders of the parental authority are of more than 18 years old and are not major protected by the law or deprived of freedom. * children among whom the relatives(parents) or the legal representatives accepted the participation of their child in this study, and having signed a lit(enlightened) consent. exclusion criteria: * children been born \> 30 limited companies and \< 28 limited companies. * children presenting a genic syndrome, an evolutionary neurological disease, a pathology malformative. * children among whom the relatives(parents) or the legal representatives refused that their child participates in the study.

Keywords: kidney-transplant recipients
study of individuals with parkinson's symptoms but in whom there is diagnostic uncertainty

Conditions: Parkinsonian Syndrome

Summary: the overall goal of this study is to evaluate the use of dopamine transporter (dat) imaging as a diagnostic tool in subjects with early parkinsonian symptoms, in whom parkinson's disease (pd) or parkinsonian syndrome (ps) is suspected, but the diagnosis remains unclear from a clinical standpoint.

* subjects will be referred to the institute for neurodegenerative disorders (ind) by practicing general neurologists with genuine uncertainty regarding the subject's diagnosis. * subjects with suspected pd or ps will be evaluated clinically and with dat imaging, using b-cit and spect. the dat imaging procedure will take place over two days: * on the first day participants are injected with \[123i\]ß cit, an investigational radioactive material that localizes in the brain. study participants will also have a thorough neurologic examination and standard neuropsychological testing, including testing of memory, concentration, abstraction and visual spatial functions. * twenty-four hours later study participants return to the institute for neurodegenerative disorders where an investigational scanning procedure will be used to obtain spect (single photon emission computed tomography) images of the brain. * subjects will be asked to return within 3 months following the imaging study to have a repeat neurological examination by the two study neurologists at ind. * subjects will be asked to return at about 6 months and possibly again at one year following the imaging study for a final clinical evaluation by one of the study neurologists at ind.

Eligibility criteria:
inclusion criteria: * age \>21 * any parkinsonian or extrapyramidal symptoms * parkinsonian symptoms for \< 2 years duration. * no significant abnormalities on screening laboratory studies including: cbc, chem-20 and urinalysis. * willingness to comply with study protocol. exclusion criteria: * pregnancy * significant medical disease including abnormalities on screening biochemical or hematological labs or abnormal electrocardiogram (ecg).

Keywords: parkinson diagnosis
tailored interventions to improve hypertension management after stroke or transient ischemic attack (tia)

Conditions: Blood Pressure

Summary: the purpose of this study is to determine the effectiveness of interventions to improve adherence to medication and healthier lifestyle choices on blood pressure over a 6 month period in a group of people at high risk for recurrent stroke events. the participants have already had a stroke or tia, and have uncontrolled blood pressure, as well as problems with memory and problem-solving, or miss taking medications, or who do not believe in the effectiveness of their medications. interventions focus on motivational interviewing, adherence counseling with memory cuing, and self-monitoring of blood pressure.

* randomized, controlled trial at 4 sites * measurement of blood pressure, missed pills, self-efficacy rating at baseline and 6 months * contacting family pharmacists to evaluate prescription renewal patterns at baseline and 6 months

Eligibility criteria:
inclusion criteria: * diagnosis of stroke or tia * hypertension * montreal cognitive assessment score less than 26 * self report of missed pills * self-efficacy rating less than 100% exclusion criteria: * inability to give informed consent * 18 years of age or younger

Keywords: hypertension stroke adherence
evaluation of inner ear and brain structures with contrast-enhanced mri in healthy subjects (hydrops)

Conditions: Meniere Disease

Summary: * this prospective study aims to better characterize inner ear's perilymphatic structures with magnetic resonance imaging using contrast media and delayed injection in healthy subjects * mr perfusion imaging will be assess in both cochlea as well * primary auditory brain pathways will be evaluated through mr diffusion imaging


Eligibility criteria:
inclusion criteria: * major subjects of over 40 years (mean age of meniere's disease 40 to 50 years) * informed consent signed * medical examination performed prior to participation in research * patients without history of inner ear disease * recipient of a french social security scheme exclusion criteria: * patients minors * patients on a legal protection regime type guardianship * respiratory pathologies, cardiovascular, renal, diabetes * claustrophobia * contraindications to exposure to a magnetic field * contraindications to injecting dotarem ®
comparison of patients' postpartum recovery using obsqor-10 score in pregnant women in vaginal delivery with and without neuraxial labor analgesia

Conditions: Analgesia

Summary: the aim of this study was to compare the postpartum recovery of pregnant women who had vaginal delivery with and without neuraxial labor analgesia using the obsqor-10 scoring system.

in this study, we planned to conduct a study to compare the postpartum recovery of pregnant women according to patient-reported outcome measures using the obsqor-10 score in vaginal deliveries with and without neuraxial labor analgesia (dural puncture epidural or combined spino epidural analgesia). in this study, after obtaining the approval of the ethics committee of atatürk university faculty of medicine hospital and written informed consent of the patients, 40 pregnant women who will deliver vaginally with or without neuraxial analgesia will be prospectively enrolled. patients will be randomized by a statistician using a computerized random numbers table and divided into 2 equal groups as group a and group b. pregnant women in group a will receive neuraxial labor analgesia (dural puncture epidural or combined spino epidural analgesia), while group b will not. if postpartum analgesic needs arise, patients in group a will receive 0.0625% bupivacaine via epidural route, while pregnant women in group b will receive iboprufen and acetaminophen if needed. obsqor-10 scores of the postpartum patients will be evaluated and recorded at discharge. in addition, basic demographic information and medical, analgesic and obstetric parameters related to the peripartum period will be recorded.

Eligibility criteria:
inclusion criteria: * being ≥18 years old * pregnant women consenting to neuraxial analgesia for labor * being ≥37 weeks gestation exclusion criteria: * patients in whom neuraxial analgesia is contraindicated * being \<18 years old * being \<37 weeks gestation